NCT06843512 Identifying Changes in Food Behaviors Associated With Beginning GLP-1 Medication
| NCT ID | NCT06843512 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Penn State University |
| Condition | Weight Loss |
| Study Type | OBSERVATIONAL |
| Enrollment | 25 participants |
| Start Date | 2025-07-15 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 25 participants in total. It began in 2025-07-15 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In recent years, GLP-1 medications have become a widely employed approach by physicians to address weight concerns in patients and lead to weight loss. Little is known, however, about how these medications may alter an individual's attitude towards food, food reactivity, or the specific types and amounts of foods an individual will choose. The purpose of this study is to observe the changes an individual experiences in their relationship and reaction to food and in their food selection prior to or within the first two weeks of taking GLP-1 medication to after three months on the medication. The researchers of this study believe that an understanding of such changes can inform questions seeking to ensure maintenance of appropriate nutrient balance within individuals on weight loss medications.
Eligibility Criteria
Inclusion Criteria: * Adults (18+) with overweight or obesity (BMI \>25 kg/m2) * Not currently taking an incretin-based medication at baseline * Recently (within two weeks) prescribed a GLP-1, can be included if they have a obesity-related co-occurring condition (diabetes, hypertension, cardiovascular disease, dyslipidemia) * Have had no prior diagnosis of cognitive or physical disability, dyslexia, or epilepsy. * Fluent in English Exclusion Criteria: * Adults (18+) without overweight or obesity * \<18 years of age at time of testing * Adults not taking a GLP-1 Medication * Adults taking a compound GLP-1 * Adults on GLP-1 medication for longer than 2 weeks at baseline * Have had a prior diagnosis of cognitive or physical disability, dyslexia, or epilepsy. * Not fluent in English
Contact & Investigator
Travis Masterson
PRINCIPAL INVESTIGATOR
The Pennsylvania State University
Frequently Asked Questions
Who can join the NCT06843512 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Weight Loss. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06843512 currently recruiting?
Yes, NCT06843512 is actively recruiting participants. Contact the research team at cmb8633@psu.edu for enrollment information.
Where is the NCT06843512 trial being conducted?
This trial is being conducted at State College, United States.
Who is sponsoring the NCT06843512 clinical trial?
NCT06843512 is sponsored by Penn State University. The principal investigator is Travis Masterson at The Pennsylvania State University. The trial plans to enroll 25 participants.